Bipolar disorder, in partial remission, most recent episode manic
Methodology & AI Transparency ⓘ
Bipolar disorder, in partial remission, most recent episode manic Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Bipolar disorder, in partial remission, most recent episode manic (F31.73; Depression, Bipolar & Mood Disorders) utilize sleep-wake rhythm assessment [Bipolar disorder, in partial remission, most recent episode manic F31.73] and objective Serum Vitamin D in Bipolar disorder, in partial remission, most recent episode manic (F31.73: & RBC Folate) targets (25(OH)D 40 – 65 ng/mL (F31.73)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Mapped to Depression, Bipolar & Mood Disorders under ICD-10-CM F31.73 for Bipolar disorder, in partial remission, most recent episode manic clinical workups.
- 3 Typical cash cost range: Differential triage of Bipolar disorder, in partial remission, most recent episode manic (F31.73) utilizes sleep-wake rhythm assessment [Bipolar disorder, in partial remission, most recent episode manic F31.73].
- 4 Top reported side effects / signs: Objective lab/clinical target for Bipolar disorder, in partial remission, most recent episode manic: Serum Vitamin D in Bipolar disorder, in partial remission, most recent episode manic (F31.73: & RBC Folate) (25(OH)D 40 – 65 ng/mL (F31.73)) and PHQ-9 Symptom Severity in Bipolar disorder, in partial remission, most recent episode manic (F31.73: Score).
Ask our AI Specialists anything about Bipolar disorder, in partial remission, most recent episode manic
What Is Bipolar disorder, in partial remission, most recent episode manic?
Physicians managing Bipolar disorder, in partial remission, most recent episode manic (F31.73; Depression, Bipolar & Mood Disorders) utilize sleep-wake rhythm assessment [Bipolar disorder, in partial remission, most recent episode manic F31.73] and objective Serum Vitamin D in Bipolar disorder, in partial remission, most recent episode manic (F31.73: & RBC Folate) targets (25(OH)D 40 – 65 ng/mL (F31.73)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Bipolar disorder, in partial remission, most recent episode manic (ICD-10 F31.73) is driven by norepinephrine [Bipolar disorder, in partial remission, most recent episode manic F31.73]; specialists in Depression, Bipolar & Mood Disorders monitor PHQ-9 Symptom Severity in Bipolar disorder, in partial remission, most recent episode manic (F31.73: Score) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Bipolar disorder, in partial remission, most recent episode manic (F31.73): disrupted sleep architecture [Bipolar disorder, in partial remission, most recent episode manic F31.73]
- • Secondary Bipolar disorder, in partial remission, most recent episode manic clinical sign: slowed concentration, indecisiveness, in Bipolar disorder, in partial remission, most recent episode manic (F31.73: and physical heaviness)
- • Symptom flares in Bipolar disorder, in partial remission, most recent episode manic correlating with Serum Vitamin D in Bipolar disorder, in partial remission, most recent episode manic (F31.73: & RBC Folate) deviation outside 25(OH)D 40 – 65 ng/mL (F31.73)
- • Functional depression & mood impact requiring sleep-wake rhythm assessment [Bipolar disorder, in partial remission, most recent episode manic F31.73] evaluation (F31.73)
Bipolar disorder, in partial remission, most recent episode manic Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F31.73 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Vitamin D in Bipolar disorder, in partial remission, most recent episode manic (F31.73: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F31.73) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Bipolar disorder, in partial remission, most recent episode manic (F31.73: Score) | < 4 (clinical remission) (F31.73) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Bipolar disorder, in partial remission, most recent episode manic (F31.73: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F31.73) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Bipolar disorder, in partial remission, most recent episode manic
Treatment selection for Bipolar disorder, in partial remission, most recent episode manic depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bipolar disorder, in partial remission, most recent episode manic)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed: What a 376-Participant Study Found Conclusions: Lumateperone 42 mg significantly improved symptoms of depression and disease severity in patients with an MDE associated with bipolar I or bipolar II disorder, with or without mixed features. The Journal of clinical psychiatry • 2023-04-24 • Phase III Randomized Trial | N = 376 | 93/100 | PMID 37103915 ↗ |
| Can This Approach Help? Inside the Latest Research on Cortical Connectivity Moderators of Antidepressant vs Placebo Treatment Response Of the participants recruited, 9 withdrew after first dose owing to reported adverse effects, and 221 participants (150 women; mean [SD] age, 37.8 [12.7] years) underwent EEG recordings and had high-quality pretreatment EEG data. JAMA psychiatry • 2020-04-01 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 31895437 ↗ |
| Can This Approach Help? Inside the Latest Research on Duration of Adjunctive Antidepressant Maintenance in Bipolar I In a trial involving patients with bipolar I disorder and a recently remitted depressive episode, adjunctive treatment with escitalopram or bupropion XL that continued for 52 weeks did not show a significant benefit as... The New England journal of medicine • 2023-08-03 • Randomized Controlled Trial | N = 90 | 88/100 | PMID 37530824 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Lumateperone for Major Depressive Episodes Associated With Lumateperone at 42 mg/day significantly improved depression symptoms and was generally well tolerated in patients with major depressive episodes associated with both bipolar I and bipolar II disorders. The American journal of psychiatry • 2021-12-15 • Phase III Randomized Trial | N = 188 | 88/100 | PMID 34551584 ↗ |
| Can This Approach Help? Inside the Latest Research on Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results Lumateperone 42-mg treatment adjunctive to lithium or valproate significantly improved depression symptoms and was generally well tolerated in patients with MDEs associated with either bipolar I or bipolar II disorder. Bipolar disorders • 2023-09-15 • Phase III Randomized Trial | N = 176 | 88/100 | PMID 36779257 ↗ |
Bipolar disorder, in partial remission, most recent episode manic Patient Community & “People Like Me” Threads
Filter Bipolar disorder, in partial remission, most recent episode manic community threads and patient logs by age, biological sex, dosage, and treatment duration.